Skip to main content
. 2022 Jun 10;14(12):2880. doi: 10.3390/cancers14122880

Figure 4.

Figure 4

MAEL regulates HCC cell sensitivity to sorafenib. (A) XTT assay indicates cell viability upon sorafenib treatment in cells with MAEL overexpression or knockout. WT, nontarget control; KO, MEAL gene knockout; EV, empty vector control. (B) Representative Annexin V/PI staining dot plots and quantification of apoptosis in cells with or without sorafenib treatment. (C) Schematic illustration of sorafenib treatment in mice implanted with PLC8024 scramble and MAEL shRNA cells. (D) Representative images and tumor volume formed in mice subcutaneously injected with MAEL modulation cells with or without sorafenib treatment (n = 5 per group). The circles stand for no tumor formatted. Scale bar stands for 1 cm. Data represent the mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.